Posted in Avandia, Friday Collection, Novartis, Oncology, Pharma, Pharma News, Pharmaceutical, tagged autism, eDetailing, Genentech, Teva on December 7, 2007 | No Comments »
The connection between high cholesterol and risk of stroke is questioned.
Is Avandia contributing to bone breakage? And more bad news for the GSK diabetes treatment…two healthcare providers drop the medication from their formularies. For switcheroos, it appears that most doctors are leaning toward Januvia or Byetta.
Long-ish article from Business Week on Genentech’s current and future [...]
Read Full Post »
Posted in Avandia, GSK, Glaxosmithkline, J&J, Lilly, Medicine, Pharma, Pharma News, Pharmaceutical, Roche, Sanofi-Aventis, Takeda, tagged acomplia, actos, forteo, fosamax, nektar, Pfizer, selling power on November 15, 2007 | No Comments »
As is becoming a more common event, this week’s news posting is being composed from an airport hotel room. My NJ ASTD colleagues are networking at the Annual Technology Training Showcase in Bridgewater; I’m in Chicago watching UConn stomp Gardner-Webb in basketball - oh, well.
It’s been another noisy week in pharma, mainly with the blacker [...]
Read Full Post »
Posted in Amylin, Avandia, Bayer, Biotech, GSK, Genentech, Genzyme, Glaxosmithkline, J&J, Johnson and Johnson, Lilly, Medical Devices, Merck, News, Novartis, Pharma, Pharma News, Pharmaceutical, Wyeth, tagged Avandia, Boston Scientific, Byetta, Doribax, Exubera, InVentiv Health, Isentress, Ixempra, Januvia, Lexiva on October 19, 2007 | 2 Comments »
The Good Stuff:
BMS gets approval for new oncology drug (for breast cancer) Ixempra.
Merck gets new HIV drug (Isentress) approved in the U.S. And, their Januvia diabetes drug gets new uses approved.
Abraxis gets cancer drugs approved.
J&J gets Doribax (for intra-abdominal and urinary tract infections) approved.
Bayer reports upbeat MS drug results.
Glaxo: new use of HIV drug Lexiva [...]
Read Full Post »
Posted in Avandia, BMS, Cephalon, Daiichi Sankyo, GSK, Glaxosmithkline, Lilly, Merck, News, Pharma, Pharma News, Pharmaceutical, Takeda on September 14, 2007 | No Comments »
Prasugrel, the upcoming rival to $6 billion drug Plavix, gets a write-up. This is a crucial new drug for co-promote partners Daiichi-Sankyo and Eli Lilly.
Good Samaritan drug rep loses leg, gains lots of supporters.
The ferment continues in the diabetes marketplace. JAMA article further muddies the waters for GSK’s Avandia, while putting a positive spin on [...]
Read Full Post »
Posted in Avandia, BMS, Biotech, Daiichi Sankyo, FDA, Forest Labs, Friday Collection, GSK, Glaxosmithkline, Healthcare, J&J, Johnson and Johnson, Marketing, Medical Devices, Novartis, Novo Nordisk, Oncology, Pharma, Pharma News, Pharmaceutical, Wyeth on August 24, 2007 | No Comments »
Novartis gets approval for Reclast, a once-per-year osteoporosis treatment. That’s a game-changer - very cool advance that should lead to far better patient compliance.
A long-ish article on Wyeth’s efforts to find Alzheimer’s treatments. It’s a risky R&D commitment, but nobody questions that desirability of finding new advances here. Also, MedAd News has a brief interview [...]
Read Full Post »
In a backside-covering move, the FDA has gone public with the “news” that it has nothing to report - yet - about possible heart risks for users of Nexium/Prilosec.
Yes, the FDA caught grief for not going public earlier with some data about Avandia. But what good is accomplished by raising issues like this when the [...]
Read Full Post »
Posted in Avandia, BMS, Blogs, GSK, Glaxosmithkline, J&J, Medical Devices, Medicine, Novartis, Oncology, Pharma, Pharma News, Pharmaceutical, Sanofi-Aventis, Schering, Takeda on August 3, 2007 | No Comments »
A minor comeback for Novartis’ Zelnorm.
Avandia gets a reprieve, of sorts…to remain on the market, but undoubtedly with a raft of warnings and cautions. Meanwhile, more encouraging data on Actos, which appears to avoid the Avandia effect. And was that data “covered up” earlier??
J&J to cut 4% of its workforce. Sanofi announces that its U.S. [...]
Read Full Post »
Posted in Amylin, AstraZeneca, Avandia, BMS, Biotech, Celgene, Impactiviti, Lilly, News, Novartis, Oncology, Pfizer, Pharma, Pharma News, Purdue, Schering, Takeda, Wyeth on July 27, 2007 | No Comments »
Two weeks worth of news articles linked here:
Medical News
Actos: safer than Avandia?
Cialis going toward a once-daily version (but shouldn’t it be once every day-and-a-half??)
Novartis gets some approvals in Europe, including new diabetes treatment Galvus
Wyeth’s Pristiq gets stalled by FDA (Pristiq is a cousin of Effexor)
GPC setback on cancer treatment
Promising HIV treatments: competitive upcoming products [...]
Read Full Post »
Posted in AstraZeneca, Avandia, BMS, Bayer, Cephalon, GSK, Glaxosmithkline, J&J, Lilly, Merck, News, Novartis, Pfizer, Pharma News, Pharmaceutical, Scandal, Schering, Takeda on June 29, 2007 | No Comments »
Some robust pipelines: Glaxo Oncology, and J&J.
Cephalon moving more rapidly on oncology candidate Treanda.
Glaxo’s cervical cancer vaccine Cervarix looking good.
Byetta, a diabetes drug from Amylin and Lilly, shows solid results after 3 years of usage.
More good press for Actos, Takeda’s competitor to Avandia.
Cholesterol agents acting against diabetic nerve pain?
Two-pronged approach to treating diabetes - the [...]
Read Full Post »
Posted in Avandia, BMS, Bayer, Biotech, Celgene, Cephalon, Genentech, Glaxosmithkline, J&J, Novartis, Oncology, Pfizer, Pharma, Pharma News, Pharmaceutical on June 8, 2007 | No Comments »
An Oncology News-fest, during ASCO week:
Genentech’s Avastin shown to be helpful for kidney cancer.
Bayer/Onyx’s Nexavar shows hopeful activity for liver cancer.
Pfizer’s still-experimental axitinib shows hopeful results with advanced thyroid cancer.
Sprycel creeping up on Gleevec as a potential first line treatment for leukemia.
Bristol’s experimental drug derived from African soil may delay progression of advanced breast cancer.
A [...]
Read Full Post »
